Skip to content

Abdominal Adiposity and Muscle Mitochondrial Functions

Study of Interaction Between Adipose and Muscle Tissues in the Control of Muscle Mitochondrial Functions

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00446745
Acronym
Mithycal
Enrollment
60
Registered
2007-03-13
Start date
2006-04-30
Completion date
2007-01-31
Last updated
2012-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitochondrial Respiratory Chain Deficiencies

Keywords

Nutritional and Metabolic Diseases, Insulin resistance, Energy Metabolisms, Skeletal muscle, Visceral Adipose Tissue

Brief summary

Numerous studies have demonstrated that excess perivisceral adipose tissue is associated with metabolic diseases such as insulin resistance. In skeletal muscle, insulin resistance has been correlated with reduced mitochondrial oxidative functions. According to the actual theory, mitochondrial dysfunctions are proposed to play a causal role in the aetiology of insulin resistance. Mechanisms involve increased intramyocellular lipids storage. Yet, the causes responsible for the decline in muscle mitochondrial functions remain to be elucidated. The investigators hypothesize that these alterations are induced by combined changes in plasma profiles of lipids and adipokines, which originate from perivisceral adipose tissue. The study aims at answering the following questions : * Are muscle mitochondrial functions altered in association with increased perivisceral adipose tissue storage? * Do changes in the pattern of plasma lipids and adipokines explain this correlation?

Detailed description

Sixty 35 to 50-years old sedentary men will be included based on their abdominal circumference (from 75 to over 102 cm). Body composition will be evaluated using dual-energy X-ray absorptiometry and perivisceral, intramuscular and intrahepatic adiposity will be assess by MRI and proton-NMR spectroscopy. Subjects will be also characterized by their glucose tolerance (OGTT), basal metabolism (indirect calorimetry) and maximal oxygen consumption (maximal aerobic power test on exercise bike). Blood samples will be collected in the fasted state to assess lipids and adipokines concentrations. Biopsies will be obtained from the vastus lateralis muscle to examine mitochondrial functions (respiration rates, ATP and superoxide anion production rates, maximal activity of oxidative enzyme). Gene expression of key enzymes, protein and transcription factors involved in lipid and energy metabolism will be assessed using real-time quantitative PCR. Finally, whole body and muscle protein metabolism will be investigated in half of the subjects using tracer infusion (incorporation of L-\[1-13C\]leucine) and biopsies from vastus lateralis, both in the post-absorptive and post-prandial states (test meal)

Interventions

None listed

Sponsors

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
35 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Male subjects * Age between 35 and 50 * waist circumference \> 75 cm * Baecke score \< 1 (activity score for sedentary subjects) * Subjects giving written informed consent * Subjects willing to comply with the study procedures * Subjects considered as normal after clinical examination and medical questionnaire

Exclusion criteria

* Weight change \> 3 kg within 3 months prior to study * Patients with type 1 or type 2 diabetes * Serologic evidence of active hepatitis B or HIV * History of cancer or significant intestinal, hepatic, renal or cardiovascular disorders within the past 5 years * History of systemic infections or inflammatory diseases within the past 2 months * Hypocaloric or special diets (e.g. vegetarian) * Patients currently known to abuse or to be dependent on any drug, including alcohol (daily consumption \> 20g) and tobacco (daily consumption \> 5 cigarettes) * CRP \< 5 mg/L * Blood coagulation disorders * Allergy to xylocaïne * for test meal : Food allergy (particularly milk allergy and lactose intolerance) * for MRI : Claustrophobia

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026